Department of Molecular Biology, Umeå University, Umeå S-90187, Sweden.
The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå S-90187, Sweden.
Antibiotics (Basel). 2016 Jun 22;5(2):23. doi: 10.3390/antibiotics5020023.
Bacterial biofilm is an emerging clinical problem recognized in the treatment of infectious diseases within the last two decades. The appearance of microbial biofilm in clinical settings is steadily increasing due to several reasons including the increased use of quality of life-improving artificial devices. In contrast to infections caused by planktonic bacteria that respond relatively well to standard antibiotic therapy, biofilm-forming bacteria tend to cause chronic infections whereby infections persist despite seemingly adequate antibiotic therapy. This review briefly describes the responses of biofilm matrix components and biofilm-associated bacteria towards sub-lethal concentrations of antimicrobial agents, which may include the generation of genetic and phenotypic variabilities. Clinical implications of bacterial biofilms in relation to antibiotic treatments are also discussed.
细菌生物膜是过去二十年中在传染病治疗中发现的一个新兴临床问题。由于包括提高生活质量的人工设备使用增加在内的多种原因,微生物生物膜在临床环境中的出现正在稳步增加。与对标准抗生素治疗反应相对较好的浮游细菌引起的感染相比,生物膜形成细菌往往会导致慢性感染,尽管看似有足够的抗生素治疗,但感染仍持续存在。本文简要描述了生物膜基质成分和生物膜相关细菌对亚致死浓度抗菌药物的反应,其中可能包括遗传和表型变异性的产生。还讨论了细菌生物膜与抗生素治疗相关的临床意义。